Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
April 18, 2024 06:30 ET
|
Cerevel Therapeutics
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with...
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
April 17, 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Ocean Drive Plastic Surgery Founder Dr. Alan Durkin Appointed VIO Med Spa Chief Medical Officer
April 17, 2024 07:48 ET
|
Ocean Drive Plastic Surgery
Dr. Alan Durkin (Ocean Drive Plastic Surgery) has been appointed Chief Medical Officer of innovative aesthetic and wellness franchise company, VIO Med Spa.
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
April 16, 2024 08:30 ET
|
TELOMIR PHARMACEUTICALS, INC.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging ...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
April 16, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata...
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 15, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
Penn Highlands Healthcare Advises How to Recognize Autism Spectrum Disorder
April 10, 2024 14:36 ET
|
Penn Highlands Healthcare
DuBois, Pennsylvania, April 10, 2024 (GLOBE NEWSWIRE) -- A toddler does not respond to their name. The child avoids eye contact. They do not talk. These could be signs that the child has autism...
CHILDREN’S WISCONSIN REMOTELY MONITORING PEDIATRIC PATIENTS VIA XEALTH AND LOCUS HEALTH
April 10, 2024 08:32 ET
|
Xealth
MILWAUKEE and SEATTLE, April 10, 2024 (GLOBE NEWSWIRE) -- Xealth, the leader in enabling digital health at scale, today announced that Children’s Wisconsin, Wisconsin’s only independent healthcare...
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated Kidney Disease (AMKD) on Capitol Hill
April 09, 2024 08:51 ET
|
American Kidney Fund
ROCKVILLE, Md., April 09, 2024 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and basketball Hall-of-Famer Alonzo Mourning are teaming up on Capitol Hill for a roundtable and policy...
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
April 07, 2024 14:45 ET
|
Esperion Therapeutics, Inc.
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in...